NASDAQ:TSHA - Taysha Gene Therapies Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $36.20
  • Forecasted Upside: 22.38 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$29.58
▲ +0.88 (3.07%)
1 month | 3 months | 12 months
Get New Taysha Gene Therapies Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TSHA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TSHA

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$36.20
▲ +22.38% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Taysha Gene Therapies in the last 3 months. The average price target is $36.20, with a high forecast of $45.00 and a low forecast of $29.00. The average price target represents a 22.38% upside from the last price of $29.58.
Buy
The current consensus among 5 polled investment analysts is to buy stock in Taysha Gene Therapies.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/25/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/23/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/21/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/20/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/19/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/17/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/16/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/15/2021

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/4/2021OppenheimerInitiated CoverageOutperform$42.00N/A
i
10/19/2020Chardan CapitalInitiated CoverageBuy$45.00High
i
Rating by G. Amusa at Chardan Capital
10/19/2020Jefferies Financial GroupInitiated CoverageBuy$34.00High
i
10/19/2020Morgan StanleyInitiated CoverageOverweight$29.00High
i
10/19/2020The Goldman Sachs GroupInitiated CoverageBuy$31.00Medium
i
(Data available from 1/15/2016 forward)
Taysha Gene Therapies logo
Taysha Gene Therapies, Inc., a gene therapy company, develops adeno-associated virus based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-101 for the treatment of GM2 gangliosidosis; TSHA-118 for the treatment of CLN1 disease; TSHA-102 for the treatment of Rett syndrome; TSHA-103 for the treatment of SLC6A1 haploinsufficiency disorder; and TSHA-104 for the treatment for Surfeit locus 1 deficiency. The company also has strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. Taysha Gene Therapies, Inc. was founded in 2019 and is based in Dallas, Texas.
Read More

Today's Range

Now: $29.58
$27.80
$30.00

50 Day Range

MA: $24.12
$19.14
$28.70

52 Week Range

Now: $29.58
$18.16
$30.96

Volume

58,524 shs

Average Volume

133,012 shs

Market Capitalization

$1.12 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Taysha Gene Therapies?

The following Wall Street analysts have issued stock ratings on Taysha Gene Therapies in the last year: Chardan Capital, Jefferies Financial Group Inc., Morgan Stanley, Oppenheimer Holdings Inc., The Goldman Sachs Group, Inc., and Zacks Investment Research.

What is the current price target for Taysha Gene Therapies?

5 Wall Street analysts have set twelve-month price targets for Taysha Gene Therapies in the last year. Their average twelve-month price target is $36.20, suggesting a possible upside of 22.4%. Chardan Capital has the highest price target set, predicting TSHA will reach $45.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $29.00 for Taysha Gene Therapies in the next year.

What is the current consensus analyst rating for Taysha Gene Therapies?

Taysha Gene Therapies currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe TSHA will outperform the market and that investors should add to their positions of Taysha Gene Therapies.

What other companies compete with Taysha Gene Therapies?

How do I contact Taysha Gene Therapies' investor relations team?

Taysha Gene Therapies' physical mailing address is 2280 Inwood Road, DALLAS TX, 75235. The company's listed phone number is 214-612-0000 and its investor relations email address is investors@tayshagtx.com. The official website for Taysha Gene Therapies is www.tayshagtx.com.